Blog

Search results : graham and harvey

Innovative investment theory and practice

Olivia London

2022-05-15 10:29:00 Sunday ET

Innovative investment theory and practice Corporate investment can be in the form of real tangible investment or intangible investment. The former concerns real asset expansion through capital expenditures and me...
+See More
Corporate payout management

Fiona Sydney

2022-05-05 09:34:00 Thursday ET

Corporate payout management This corporate payout literature review rests on the recent survey article by Farre-Mensa, Michaely, and Schmalz (2014). Out of the conventional motives of why the typical firm makes c...
+See More
Corporate diversification theory and evidence

James Campbell

2022-04-05 17:39:00 Tuesday ET

Corporate diversification theory and evidence A recent strand of corporate diversification literature spans at least three generations. The first generation suggests that corporate diversification typically erodes...
+See More
Capital structure theory and practice

Jonah Whanau

2022-03-15 10:32:00 Tuesday ET

Capital structure theory and practice  The genesis of modern capital structure theory traces back to the seminal work of Modigliani and Miller (1958, 1963). This work not only leads to the core testable propo...
+See More
1


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.
Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More
Edge strategies help business leaders improve core products and services in a more cost-effective and less risky way.
John Fourier

2020-09-24 10:26:00 Thursday ET

Edge strategies help business leaders improve core products and services in a more cost-effective and less risky way.

Edge strategies help business leaders improve core products and services in a more cost-effective and less risky way. Alan Lewis and Dan McKone (2016)

+See More
American CEOs of about 200 corporations issue a joint statement in support of stakeholder value maximization.
Becky Berkman

2019-10-23 15:39:00 Wednesday ET

American CEOs of about 200 corporations issue a joint statement in support of stakeholder value maximization.

American CEOs of about 200 corporations issue a joint statement in support of stakeholder value maximization. The Business Roundtable offers this statement

+See More
Management consultants can build sustainable trust-driven client relations through the accelerant curve of business value creation.
Monica McNeil

2020-11-17 08:27:00 Tuesday ET

Management consultants can build sustainable trust-driven client relations through the accelerant curve of business value creation.

Management consultants can build sustainable trust-driven client relations through the accelerant curve of business value creation. Alan Weiss (2016)

+See More
AYA fintech finbuzz analytic report on the global macro economic outlook Winter-Spring 2020
Andy Yeh Alpha

2020-02-02 11:32:00 Sunday ET

AYA fintech finbuzz analytic report on the global macro economic outlook Winter-Spring 2020

Our fintech finbuzz analytic report shines fresh light on the current global economic outlook. As of Winter-Spring 2020, the analytical report delves into t

+See More
Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.
Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More